Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G
Rattachement africain : cn, gr, de, rs, ca, ru, us, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results.Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment.Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients.Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50.Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf.Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones.Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy.Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Results:The relationships between changes of performance status and disease progression were examined via a single correspondence analysis.The two-dimensional scores (coordinates) derived from the correspondence analysis were then regressed against the predictors to form distinct splits and nodes obtaining quantitative results.The best fit is usually achieved by lowering exhaustively the AICc criterion and looking in parallel the change of R 2 expecting improvements more than 5%.both types of therapy are capable of producing best ameliorative effects, when either the programmed death-ligand-1 expression or parenchymal site in joint with low pack years are present in the sampling data.Conclusions: Intratumoral treatment combination with cisplatin plus immunotherapy indifferent of nivolumab or pembrolizumab combination is an effective choice.In specific for those with endobronchial lesions.Moreover; patients with programmed death-ligand-1 ≥ 50 had their performance status and disease progression improved over the eight month observation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G
- Date Crossref
- 01/01/2021
- Éditeur
- Ivyspring International Publisher
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Second Military Medical University Department of Respiratory & Critical Care Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Aristotle University of Thessaloniki pays non établi dans la noticeUniversité ou école supérieure
-
AHEPA University Hospital pays non établi dans la noticeÉtablissement de santé
-
Changhai Hospital . Department of Respiratory and Critical Care Medicine pays non établi dans la noticeÉtablissement de santé
-
Sana Kliniken AG pays non établi dans la noticeÉtablissement de santé
-
Nanjing Maternity and Child Health Care Hospital pays non établi dans la noticeÉtablissement de santé
-
Changzhou No.2 People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Interbalkan Medical Center pays non établi dans la noticeÉtablissement de santé
-
University of Novi Sad pays non établi dans la noticeUniversité ou école supérieure
-
Institute of Public Health of Vojvodina pays non établi dans la noticeUniversité ou école supérieure
-
Institute for Pulmonary Diseases of Vojvodina pays non établi dans la noticeÉtablissement de santé
-
Cytodiagnostics (Canada) pays non établi dans la noticeEntreprise
Department of Respiratory & Critical Care Medicine — Second Military Medical University, Aristotle University of Thessaloniki et AHEPA University Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.